Revenue
2018
2019
2020
2021
2022
2023
2024
2025
Inventiva (IVA)
Price€3.23Cached quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | €4.5M | €9.2M | €17.5M | €12.2M | €4.2M | €372,000 | €7.0M | €3.2M |
| Research & development | €87.0M | €90.9M | €110.0M | €60.5M | €48.5M | €23.7M | €33.8M | €31.8M |
| Operating expenses | €137.4M | €103.2M | €120.1M | €69.0M | — | — | — | — |
| Operating income | −€141.0M | −€97.6M | −€102.7M | −€57.1M | −€52.1M | −€29.7M | −€30.3M | −€32.9M |
| Operating margin | −3,145.51% | −1,060.64% | −587.68% | −468.92% | −1,242.58% | −7,988.71% | −433.15% | −1,029.18% |
| EBITDA | −€317.3M | −€166.5M | −€102.0M | −€51.9M | −€51.2M | −€28.8M | −€29.1M | — |
| EBITDA margin | −7,078.43% | −1,810.45% | −583.86% | −426.05% | −1,221.13% | −7,746.77% | −416.00% | — |
| Net income | −€354.1M | −€184.2M | −€110.4M | −€54.3M | −€49.6M | −€33.6M | −€30.2M | −€33.0M |
| Net profit margin | −7,899.58% | −2,002.74% | −631.84% | −445.64% | −1,183.48% | −9,037.37% | −431.81% | −1,032.66% |
| Basic EPSper basic share | -€1.90 | -€3.08 | -€2.43 | -€1.31 | -€1.27 | -€0.99 | -€1.28 | -€1.61 |
| Diluted EPSper diluted share | -€1.90 | -€3.08 | -€2.43 | -€1.31 | -€1.27 | -€0.99 | -€1.28 | -€1.61 |
Owners
Reported shareholders and owner groups
7.70%of company shares
InvusSource updated Sep 2, 2026
View holders
| Holder | Ownership |
|---|---|
Invus | 7.70%Sep 2, 2026 |
Sofinnova Partners SAS | 7.30%Sep 2, 2026 |
Andera Partners SCA | 6.80%Sep 2, 2026 |
Samsara BioCapital L.P. | 6.50%Sep 2, 2026 |
Deep Track Biotechnology Master Fund, Ltd. | 5.20%Sep 2, 2026 |
Eventide Healthcare Innovation Fund I, LP | 5.00%Sep 2, 2026 |
Frédéric Cren | 2.80%Sep 2, 2026 |
Pierre Broqua | 1.80%Sep 2, 2026 |
Employees | 1.20%Sep 2, 2026 |
These Euronext company-profile figures report shares in the company's capital. Named holders and owner groups are shown as published; free float, treasury shares, and unspecified holders are excluded from the colored segments.
Gray completes the 100% scale; it is not an estimate of other owners.
Source: Euronext / Cofisem ↗Checked Sep 27, 2026
Insider buys & sells
Community posts
Inventiva reports €69.5 million loss ahead of pivotal readout
Inventiva ($IVA) reported a first-half net loss of €69.5 million, compared with €175.9 million a year earlier. Research and development spending increased to €46.2 million, while general and administrative expenses rose to €22.2 million as ...
